Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Gardiquimod
60
CHF
CHF 60.00
In stock
AG-CR1-3583-M0055 mgCHF 60.00
AG-CR1-3583-M02525 mgCHF 180.00
| Product Details | |
|---|---|
| Synonyms | 1-(4-Amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol |
| Product Type | Chemical |
| Properties | |
| Formula |
C17H23N5O |
| MW | 313.4 |
| CAS | 1020412-43-4 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥98% |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO (30mg/ml), dioxane (5mg/ml), methanol (30mg/ml) or acetonitrile (2mg/ml). |
| InChi Key | FHJATBIERQTCTN-DZQCGVKKCV |
| Smiles | CCNCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Immune response modifier.
- Antiviral and antitumor compound
- Selective ligand for human or mouse Toll-like receptor 7 (TLR7).
- Induces the activation of NF-κB in HEK 293 cells expressing TLR7 at 0.1µg/ml. 10 times more active than Imiquimod (Prod. No. AG-CR1-3569).
- At high concentrations (3µg/ml) slightly activates TLR8.
- Shows adjuvant activity to increase the effectiveness of vaccines.
Product References
- Double-Stranded RNA Induces an Antiviral Defense Status in Epidermal Keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-Mediated Differential Signaling: B.N. Kalali, et al.; J. Immunol. 181, 2694 (2008)
- Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod: J. Zhu, et al.; Mol. Immunol. 45, 3238 (2008)
- Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline: N.M. Shukla, et al.; Bioorg. Med. Chem. Lett. 19, 2211 (2009)
- Intradermal immunization improves protective efficacy of a novel TB vaccine candidate: S.L. Baldwin, et al; Vaccine 27, 3063 (2009)
- Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells: N.A. Forward, et al.; J. Leukoc. Biol. 87, 117 (2010)
- The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice: F. Ma, et al.; Cell Mol. Immunol. 7, 381 (2010)
- TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity: J. Du, et al.; Vaccine 28, 6273 (2010)
- TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother., ahead of print (2018)
Related Products
